This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2003, p. 1135-1136, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.1135-1136.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae

Patricia M. Roblin, Tamara Reznik, Andrei Kutlin, and Margaret R. Hammerschlag*

Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098

Received 15 July 2002/ Returned for modification 30 October 2002/ Accepted 15 November 2002

ABI-1648 (rifalazil) is a semisynthetic rifamycin with potent bactericidal activity against intracellular respiratory bacteria, including Mycobacterium tuberculosis, and a long half-life (~60 h) and thus can be administered once weekly. We therefore tested the in vitro activities of ABI-1648, its derivatives ABI-1657 and ABI-1131, azithromycin, and levofloxacin against 10 strains of Chlamydia trachomatis and 10 recent clinical isolates of Chlamydia pneumoniae. The MICs at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed for ABI-1648, ABI-1657, and ABI-1131 were 0.0025 µg/ml for C. trachomatis and 0.00125 to 0.0025 µg/ml for C. pneumoniae. ABI-1648, ABI-1657, and ABI-1131 were 10- to 1,000-fold more active than azithromycin and levofloxacin.

* Corresponding author. Mailing address: Department of Pediatrics, Box 49, SUNY Downstate Medical Center, 450 Clarkson Ave., Brooklyn, NY 11203-2098. Phone: (718) 245-4075. Fax: (718) 245-2118. E-mail: mhammerschlag{at}pol.net.

Antimicrobial Agents and Chemotherapy, March 2003, p. 1135-1136, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.1135-1136.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Campbell, L. A., Kuo, C.-C., Suchland, R. J., Rothstein, D. M. (2008). Efficacy of Benzoxazinorifamycins in a Mouse Model of Chlamydia pneumoniae Lung Infection. Antimicrob. Agents Chemother. 52: 1855-1858 [Abstract] [Full Text]  
  • Rothstein, D. M., Farquhar, R. S., Sirokman, K., Sondergaard, K. L., Hazlett, C., Doye, A. A., Gwathmey, J. K., Mullin, S., van Duzer, J., Murphy, C. K. (2006). Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection. Antimicrob. Agents Chemother. 50: 3658-3664 [Abstract] [Full Text]  
  • Suchland, R. J., Brown, K., Rothstein, D. M., Stamm, W. E. (2006). Rifalazil Pretreatment of Mammalian Cell Cultures Prevents Subsequent Chlamydia Infection. Antimicrob. Agents Chemother. 50: 439-444 [Abstract] [Full Text]  
  • Labro, M. T., Ollivier, V., Babin-Chevaye, C. (2005). Interaction of Rifalazil with Oxidant-Generating Systems of Human Polymorphonuclear Neutrophils. Antimicrob. Agents Chemother. 49: 5018-5023 [Abstract] [Full Text]  
  • Xia, M., Suchland, R. J., Carswell, J. A., Van Duzer, J., Buxton, D. K., Brown, K., Rothstein, D. M., Stamm, W. E. (2005). Activities of Rifamycin Derivatives against Wild-Type and rpoB Mutants of Chlamydia trachomatis. Antimicrob. Agents Chemother. 49: 3974-3976 [Abstract] [Full Text]  
  • Anderson, J. L. (2005). Infection, Antibiotics, and Atherothrombosis -- End of the Road or New Beginnings?. NEJM 352: 1706-1709 [Full Text]  
  • Kutlin, A., Kohlhoff, S., Roblin, P., Hammerschlag, M. R., Riska, P. (2005). Emergence of Resistance to Rifampin and Rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob. Agents Chemother. 49: 903-907 [Abstract] [Full Text]  
  • Suchland, R. J., Bourillon, A., Denamur, E., Stamm, W. E., Rothstein, D. M. (2005). Rifampin-Resistant RNA Polymerase Mutants of Chlamydia trachomatis Remain Susceptible to the Ansamycin Rifalazil. Antimicrob. Agents Chemother. 49: 1120-1126 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»